Dixon Hubard Feinour & Brown Inc Halozyme Therapeutics, Inc. Transaction History
Dixon Hubard Feinour & Brown Inc
- $842 Million
- Q2 2022
A detailed history of Dixon Hubard Feinour & Brown Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Dixon Hubard Feinour & Brown Inc holds 20,218 shares of HALO stock, worth $949,437. This represents 0.11% of its overall portfolio holdings.
Number of Shares
20,218
Previous 20,218
-0.0%
Holding current value
$949,437
Previous $806,000
10.42%
% of portfolio
0.11%
Previous 0.08%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$827 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$606 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$312 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$191 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$160 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.54B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...